A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Summary

The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Chinese participants with type 2 diabetes mellitus who are on a stable dose of basal insulin. Side effects and tolerability will be documented. Blood samples will be taken to assess how the body processes the study drug and the effect of the study drug on blood sugar levels. The study will last up to 18 weeks and may include 18 visits for each participant.

Timeline

Start

2022-11-30

Primary completion

2023-10-10

Completion

2023-10-10

Publications

• Liu H, Fan Y, Wang Y, Yuan Y, Leohr JK, Liu M, Yu Y. Pharmacokinetics, Pharmacodynamics, and Safety of Once-Weekly Insulin Efsitora Alfa in Chinese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled Trial. Adv Ther. 2026 Jul 9. doi: 10.1007/s12325-026-03678-1. Online ahead of print.

Drugs

Indications